|Bid||181.12 x 800|
|Ask||0.00 x 1000|
|Day's Range||190.68 - 193.80|
|52 Week Range||142.81 - 217.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||2.88 (1.52%)|
|1y Target Est||211.58|
The finalized deal between Almirall and Allergan involves four approved products and one under FDA review
Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017. Analysts expect Shire’s net adjusted income to increase to $4.68 billion in 2018 compared to its net adjusted income of $4.60 billion in 2017. Shire’s stock price has risen nearly 15.4% in the last 12 months, and it’s risen ~15.7% year-to-date in 2018.
Botox has grown into a giant product thanks largely to older people seeking wrinkle treatments. Total sales of the treatment, which is also used for medical purposes, neared $1 billion in the second quarter. Now corporations and venture firms aim to provide aesthetic products to younger consumers.
Allergan (AGN) reported revenue of $4.1 billion in the second quarter, a 2.9% YoY (year-over-year) rise in revenue compared to its revenue of $4.0 billion in the second quarter of 2017.
DUBLIN, Sept. 20, 2018 /PRNewswire/ -- Allergan plc (AGN) today announced a partnership with actor Scott Eastwood in honor of World Alzheimer's Day, September 21, a day used as a focal point by organizations globally to raise awareness for Alzheimer's disease and the sacrifices caregivers make every day for their loved ones. Through combined efforts, Allergan and Scott Eastwood hope to widely deliver the message that it is important for those affected by Alzheimer's to be well-informed, pointing to Allergan's educational website LearnAboutAlz.com as a resource.
CHENGDU, China, Sept. 19, 2018 /PRNewswire/ -- Allergan, a global pharmaceutical company and leader in medical aesthetics, today announced plans to open its first Medical Aesthetics Innovation Center in Chengdu China in early 2019. The center, to be located at the High-Tech Zone of Chengdu, will feature a world-class training center for medical aesthetics healthcare professionals, as well as an education and product experience center for medical aesthetics consumers.
In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
Prospects are looking brighter for Teva Pharmaceuticals Industries Limited (NYSE:TEVA). The company won a pair of FDA approvals in September. The big news here is the FDA approving its migraine treatment.
In this article, we’ll compare the EPS growth rates of pharmaceutical companies Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
Revance Therapeutics Inc (NASDAQ: RVNC ), a biotech company developing a botulinum toxin product, could face a competitive backlash, according to JMP Securities. The Analyst Analyst Donald Ellis downgraded ...
The US pharmaceutical sector is made up of players that include drug manufacturers, drug marketers, and biotechnology companies.
Allergan (AGN) presents positive results from a study, evaluating a higher dose of Botox for the treatment of glabellar lines.
DUBLIN, Sept. 14, 2018 /PRNewswire/ -- Allergan plc (AGN) today announced clinical study results of higher doses of BOTOX® Cosmetic compared to BOTOX® Cosmetic 20 unit dose at week 24 in patients with moderate to severe glabellar lines.
U.S. health regulators say they'll convene a public meeting of medical advisers next year to discuss new science on breast implant safety, including an independent analysis that suggests certain rare health problems might be more common with silicone gel implants.
DUBLIN, Sept. 14, 2018 /PRNewswire/ -- Allergan plc (AGN) today hosted its first ever Medical Aesthetics Analyst Day where the Company outlined its industry-leading portfolio and pipeline and key initiatives to drive future growth, as well as presented an overview of the global medical aesthetics market.
Allergan Plc (AGN.N) said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox. The drugmaker announced earlier on Friday the acquisition of Bonti Inc, which makes a shorter-acting neurotoxin than Botox. Allergan is also doubling its investment in direct-to-consumer ad spending and beefing up its sales force as companies like Revance Therapeutics Inc (RVNC.O) and Evolus Inc (EOLS.O) vie to wrest market share with rival treatments to Botox.
The drugmaker announced earlier on Friday the acquisition of Bonti Inc, which makes a shorter-acting neurotoxin than Botox. Allergan is also doubling its investment in direct-to-consumer ad spending and beefing up its sales force as companies like Revance Therapeutics Inc and Evolus Inc vie to wrest market share with rival treatments to Botox. The company made the announcements at its Medical Aesthetics Day in New York.
’s 2008 hit, “I Kissed a Girl.” Potential customers viewing the ad likely won’t need any medical treatment to raise their eyebrows. The ad fits with Allergan’s effort to boost sales of Botox by marketing it to younger people and to men.
A look at the shareholders of Allergan plc (NYSE:AGN) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual toRead More...
Allergan PLC said Friday it would acquire neurotoxin product developer Bonti Inc. for an up-front payment of $195 million.
DUBLIN and NEWPORT BEACH, Calif., Sept. 14, 2018 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company, today announced it has agreed to acquire Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Following completion of the acquisition, Allergan will obtain global rights to Bonti's pipeline consisting of two botulinum neurotoxin serotype E (BoNT/E) programs currently in Phase 2 development, EB-001A (aesthetic) and EB-001T (therapeutic).